Previous close | 0.1000 |
Open | 0.3000 |
Bid | 0.0000 |
Ask | 0.7500 |
Strike | 20.00 |
Expiry date | 2024-05-17 |
Day's range | 0.1000 - 0.3000 |
Contract range | N/A |
Volume | |
Open interest | 13 |
CRANBURY, N.J., May 10, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced longer-term data updates from its lentiviral (LV) vector hematology portfolio presented at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Data updates demonstrate the continued safety and efficacy of the Phase 1/2 pivotal stud
Rocket Pharmaceuticals' (RCKT) first-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
CRANBURY, N.J., May 06, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the quarter ending March 31, 2024.